Tetraphase antibiotic reaches patient halfway point in Phase III

|About: Tetraphase Pharmaceuticals (TTPH)|By:, SA News Editor

Tetraphase Pharmaceuticals (TTPH) has enrolled 50% of the 536 patients that it plans to recruit for the first Phase III trial of its lead antibiotic candidate Eravacycline, which is designed to treat multidrug-resistant (MDR) infections.

The study, called Ignite, is assessing the therapy for complicated intra-abdominal infections.

Tetraphase has also started enrolling patients for a two-part Phase III trial called Ignite 2 for testing Eravacycline for complicated urinary tract infections. (PR)